Article Text

Download PDFPDF

888 Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models
  1. Kana Ichikawa1,
  2. Ammar Adam1,
  3. Hsin-Jung Wu2,
  4. David Lahr1,
  5. Lan Xu3,
  6. Brandon Antonakos1,
  7. Liv Johannessen1,
  8. Steven Bellon1,
  9. Ryan Kruger1,
  10. Richard Centore1 and
  11. Martin Hentemann1
  1. 1Foghorn Therapeutics, Cambridge, MA, United States
  2. 2Blueprint Medicines, Cambridge, MA, United States
  3. 3Ikena Oncology, Boston, MA, United States


Background The BAF family of chromatin remodeling complexes are critical regulators of chromatin accessibility and gene expression, and BRM and BRG1 (also known as SMARCA2 and SMARCA4), the catalytic subunits of BAF, provide the enzymatic activity required for chromatin remodeling activity. We have previously identified and characterized a series of novel dual inhibitors of the BRM/BRG1 ATPases, and FHD-286, a potent and selective BRM/BRG1 inhibitor, is currently under clinical investigation for the treatment of metastatic uveal melanoma and advanced hematological malignancies (NCT04879017 and NCT04891757). BAF chromatin remodeling complex activities are implicated in many immunologic responses, and previous studies have shown the involvement of PBAF in the regulation of antitumor immunity.1

Methods Given the recent reports correlating SMARCA4 deficiency and ICI response,2 we explored the combination of BRM/BRG1 ATPase inhibition and anti-PD-1 antibody in syngeneic mouse models from various lineages and with different sensitivities to checkpoint inhibition.

Results The combination of FHD-286 and anti-PD-1 antibody provided synergistic efficacy and survival benefit compared to anti-PD-1 alone in A20, CT26, and the immunologically barren B16F10 melanoma model. FHD-286 increased MHCI expression on B16F10 cells, and increases in IFNγ and Th1-type chemokine CXCL10 levels were observed in immunocompetent mice following treatment, suggesting that combinatorial activity may result from effects on both the tumor and the immune system.

Conclusions FHD-286 has the potential to sensitize tumor to immune-checkpoint inhibition and represents a novel combination approach for cancer immunotherapy.


  1. Pan D, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018; 359:770–775.

  2. Zhou M, et al. Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. Oncogenesis. 2021; 10:3.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.